Targeting the NRXN3/RSK1/FBXO1/caspase-3 axis emerges as a promising strategy for ICC treatment, with the potential to improve chemosensitivity and survival. This evidence concerns the gene RPS6KA1 and intrahepatic cholangiocarcinoma.